CHICAGO, May 1, 2013 /PRNewswire/ -- Positron
Corporation (OTCBB: POSC) is pleased to announce the release of the
PosiRx® 3000-Series, its latest pharmacy automation systems. The
PosiRx® 3000-Series are the first systems to automate and encompass
the complete compounding process, from generator elution to dose
distribution, of multiple diagnostic SPECT agents in an environment
engineered to be ISO Class 5 and USP 797 compliant. Designed
for facilities dispensing as many as three hundred patient-specific
doses per day, the PosiRx® 3000-Series will benefit providers and
patients by enabling unit dose radiopharmaceuticals to be prepared
more cost effectively and accurately than previously possible.
The PosiRx® line of automation systems features DoseLink™,
Positron's state of the art proprietary software. Developed for
precision and customer ease of use, DoseLink™ maximizes the
functionality and efficiency of operating the PosiRx® system
through a robust and intuitive interface that can be operated from
a variety of interfaces. Whether accessed from a desktop,
tablet or smartphone, DoseLink™ empowers the user to control drug
preparation and plan daily production, as well as store and
retrieve data in a secure environment. Additionally, the
operator may interact with Positron support personnel for
assistance with any task in real time, across any platform.
"The release of the PosiRx® 3000-Series is a true milestone that
marks the next phase in nuclear pharmacy automation," stated
Charles Conroy, RPh, MBA, Positron's
Chief Operating Officer. "For over 20 years, the nuclear pharmacy
community has been seeking an automation solution that can
efficiently and accurately prepare patient specific unit doses.
Through the ability to compound a wide selection of
radiopharmaceuticals, coupled with the system's speed and
efficiency, the 3000-Series is that solution and stands in a class
by itself. By powering the System with DoseLink™, PosiRx®
users will benefit from the unprecedented flexibility and control
to operate across all types of devices and a variety of
platforms. By controlling the preparation process from any
place at any time, our customers will see significant revenue
enhancement from increased patient throughput and a decrease in
cost of goods."
"We are pleased to continue Positron's 30-year legacy of
innovation," stated Patrick G.
Rooney, Positron's Chief Executive Officer, "As we begin the
installations of multiple pre-ordered systems, we are excited to be
the first to bring this revolutionary technology to market."
To support our commercialization efforts, Positron has launched
a dedicated website for the PosiRx® portfolio of products,
www.posirx.com. The new website is part of Positron's plan to
further develop its corporate identity and is designed to help
distinguish between the Company's cardiac PET business and high
tech automation products. By highlighting innovative features
and further expanding its capabilities, the site allows visitors to
gain a comprehensive understanding of the PosiRx® System.
Conroy added, "The PosiRx® system with DoseLink™ software
provides a solid platform for growth into other diagnostic areas,
additional pharmaceutical classes and new markets. The dedicated
website will be very important as we work with our partners to
expand Positron's offerings."
About Positron: Positron Corporation is a nuclear
medicine healthcare company vertically integrating key segments of
nuclear cardiology—providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes solutions, Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. Positron is redefining the industry. More
information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation